{"url_path":"/sec/abvc/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1173313/0001213900-26-058104-index.html","accession_number":"0001213900-26-058104","cik":"0001173313","ticker":"ABVC","issuer_name":"ABVC BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1173313/0001213900-26-058104-index.html","primary_entity_key":"0001173313","primary_entity_name":"ABVC BIOPHARMA, INC."},"word_count":60,"has_tables":true,"body_markdown":"**ITEM 5. OTHER INFORMATION.**\n\n \n\n \n(a)\nNone.\n\n \n\n \n(b)\nNone.\n\n \n\n  (c) During the three  months ended March 31, 2026, none of our officers or directors, as defined in Rule 16a-1(f), informed us of the adoption, modification or termination of any “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.\n\n \n\n21"}